NHS introduces Pfizer’s tafamidis for ATTR-CM treatment
The UK NHS has introduced Pfizer's tafamidis for transthyretin amyloidosis cardiomyopathy (ATTR-CM), a rare heart condition.
The UK NHS has introduced Pfizer's tafamidis for transthyretin amyloidosis cardiomyopathy (ATTR-CM), a rare heart condition.
What's Your Reaction?
